Molecular Recognition of CCR5 by an HIV-1 Gp120 V3 Loop

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2014 Apr 26

PMID 24763408

Citations 36

Authors

Phanourios Tamamis

Christodoulos A Floudas

Affiliations

Soon will be listed here.

Abstract

The binding of protein HIV-1 gp120 to coreceptors CCR5 or CXCR4 is a key step of the HIV-1 entry to the host cell, and is predominantly mediated through the V3 loop fragment of HIV-1 gp120. In the present work, we delineate the molecular recognition of chemokine receptor CCR5 by a dual tropic HIV-1 gp120 V3 loop, using a comprehensive set of computational tools predominantly based on molecular dynamics simulations and free energy calculations. We report, what is to our knowledge, the first complete HIV-1 gp120 V3 loop : CCR5 complex structure, which includes the whole V3 loop and the N-terminus of CCR5, and exhibits exceptional agreement with previous experimental findings. The computationally derived structure sheds light into the functional role of HIV-1 gp120 V3 loop and CCR5 residues associated with the HIV-1 coreceptor activity, and provides insights into the HIV-1 coreceptor selectivity and the blocking mechanism of HIV-1 gp120 by maraviroc. By comparing the binding of the specific dual tropic HIV-1 gp120 V3 loop with CCR5 and CXCR4, we observe that the HIV-1 gp120 V3 loop residues 13-21, which include the tip, share nearly identical structural and energetic properties in complex with both coreceptors. This result paves the way for the design of dual CCR5/CXCR4 targeted peptides as novel potential anti-AIDS therapeutics.

Citing Articles

Stronger binding affinities of in provide insights into HIV/host interactions.

Li V, Lee C, Park T, Jarvis E, Kim H Infect Dis Model. 2024; 10(1):287-301.

PMID: 39620069 PMC: 11607582. DOI: 10.1016/j.idm.2024.10.003.

In Vitro and In Silico Antiviral Activity of Di-Halogenated Compounds Derived from L-Tyrosine against Human Immunodeficiency Virus 1 (HIV-1).

Serna-Arbelaez M, Garcia-Carcamo V, Rincon-Tabares D, Guerra D, Loaiza-Cano V, Martinez-Gutierrez M Curr Issues Mol Biol. 2023; 45(10):8173-8200.

PMID: 37886959 PMC: 10605077. DOI: 10.3390/cimb45100516.

Downregulation of CCR5 on brain perivascular macrophages in simian immunodeficiency virus-infected rhesus macaques.

Hattler J, Irons D, Luo J, Kim W Brain Behav. 2023; 13(8):e3126.

PMID: 37366075 PMC: 10454275. DOI: 10.1002/brb3.3126.

Novel small synthetic HIV-1 V3 crown variants: CCR5 targeting ligands.

Anitha A, Narayanan P, Ajayakumar N, Sivakumar K, Kumar K J Biochem. 2022; 172(3):149-164.

PMID: 35708645 PMC: 9445593. DOI: 10.1093/jb/mvac052.

Triazolyl Ru(II), Os(II), and Ir(III) complexes as potential HIV-1 inhibitors.

Putterill B, Rono C, Makhubela B, Meyer D, Gama N Biometals. 2022; 35(4):771-784.

PMID: 35699796 DOI: 10.1007/s10534-022-00400-w.

References

Feig M . Implicit membrane models for membrane protein simulation. Methods Mol Biol. 2008; 443:181-96. DOI: 10.1007/978-1-59745-177-2_10. View

Humphrey W, Dalke A, Schulten K . VMD: visual molecular dynamics. J Mol Graph. 1996; 14(1):33-8, 27-8. DOI: 10.1016/0263-7855(96)00018-5. View

Farzan M, Mirzabekov T, Kolchinsky P, Wyatt R, Cayabyab M, Gerard N . Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell. 1999; 96(5):667-76. DOI: 10.1016/s0092-8674(00)80577-2. View

MacKerell A, Bashford D, Bellott M, Dunbrack R, Evanseck J, Field M . All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B. 2014; 102(18):3586-616. DOI: 10.1021/jp973084f. View

Lazaridis T . Effective energy function for proteins in lipid membranes. Proteins. 2003; 52(2):176-92. DOI: 10.1002/prot.10410. View

Bozek K, Lengauer T, Sierra S, Kaiser R, Domingues F . Analysis of physicochemical and structural properties determining HIV-1 coreceptor usage. PLoS Comput Biol. 2013; 9(3):e1002977. PMC: 3605109. DOI: 10.1371/journal.pcbi.1002977. View

Berro R, Sanders R, Lu M, Klasse P, Moore J . Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry. PLoS Pathog. 2009; 5(8):e1000548. PMC: 2718843. DOI: 10.1371/journal.ppat.1000548. View

Tamamis P, de Victoria A, Gorham Jr R, Bellows-Peterson M, Pierou P, Floudas C . Molecular dynamics in drug design: new generations of compstatin analogs. Chem Biol Drug Des. 2012; 79(5):703-18. PMC: 3319835. DOI: 10.1111/j.1747-0285.2012.01324.x. View

Chandramouli B, Chillemi G, Abbate I, Capobianchi M, Rozera G, Desideri A . Importance of V3 loop flexibility and net charge in the context of co-receptor recognition. A molecular dynamics study on HIV gp120. J Biomol Struct Dyn. 2012; 29(5):879-91. DOI: 10.1080/07391102.2012.10507416. View

10.

Dragic T . An overview of the determinants of CCR5 and CXCR4 co-receptor function. J Gen Virol. 2001; 82(Pt 8):1807-1814. DOI: 10.1099/0022-1317-82-8-1807. View

11.

Siciliano S, Kuhmann S, Weng Y, Madani N, Springer M, Lineberger J . A critical site in the core of the CCR5 chemokine receptor required for binding and infectivity of human immunodeficiency virus type 1. J Biol Chem. 1999; 274(4):1905-13. DOI: 10.1074/jbc.274.4.1905. View

12.

Rabut G, Konner J, Kajumo F, Moore J, Dragic T . Alanine substitutions of polar and nonpolar residues in the amino-terminal domain of CCR5 differently impair entry of macrophage- and dualtropic isolates of human immunodeficiency virus type 1. J Virol. 1998; 72(4):3464-8. PMC: 109856. DOI: 10.1128/JVI.72.4.3464-3468.1998. View

13.

Farzan M, Choe H, Vaca L, Martin K, Sun Y, DESJARDINS E . A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5. J Virol. 1998; 72(2):1160-4. PMC: 124591. DOI: 10.1128/JVI.72.2.1160-1164.1998. View

14.

Li W, Godzik A . Cd-hit: a fast program for clustering and comparing large sets of protein or nucleotide sequences. Bioinformatics. 2006; 22(13):1658-9. DOI: 10.1093/bioinformatics/btl158. View

15.

Suphaphiphat P, Thitithanyanont A, Paca-Uccaralertkun S, Essex M, Lee T . Effect of amino acid substitution of the V3 and bridging sheet residues in human immunodeficiency virus type 1 subtype C gp120 on CCR5 utilization. J Virol. 2003; 77(6):3832-7. PMC: 149532. DOI: 10.1128/jvi.77.6.3832-3837.2003. View

16.

Hill C, Kwon D, Jones M, Davis C, Marmon S, Daugherty B . The amino terminus of human CCR5 is required for its function as a receptor for diverse human and simian immunodeficiency virus envelope glycoproteins. Virology. 1998; 248(2):357-71. DOI: 10.1006/viro.1998.9283. View

17.

Tamamis P, Morikis D, Floudas C, Archontis G . Species specificity of the complement inhibitor compstatin investigated by all-atom molecular dynamics simulations. Proteins. 2010; 78(12):2655-67. PMC: 3138065. DOI: 10.1002/prot.22780. View

18.

Haberthur U, Caflisch A . FACTS: Fast analytical continuum treatment of solvation. J Comput Chem. 2007; 29(5):701-15. DOI: 10.1002/jcc.20832. View

19.

de Victoria A, Tamamis P, Kieslich C, Morikis D . Insights into the structure, correlated motions, and electrostatic properties of two HIV-1 gp120 V3 loops. PLoS One. 2012; 7(11):e49925. PMC: 3501474. DOI: 10.1371/journal.pone.0049925. View

20.

Gorny M, Revesz K, Williams C, Volsky B, Louder M, Anyangwe C . The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope. J Virol. 2004; 78(5):2394-404. PMC: 369230. DOI: 10.1128/jvi.78.5.2394-2404.2004. View